glp-1 drug news today Retatrutide for weight loss: Study shows 30% body weight loss The GLP-1 revolution: What UAB

Kanoski SE, Rupprecht LE, Fortin SM, et al

For patients with severe obesity-related complications, providers may lean toward therapies with the strongest efficacy data currently available

Agents, such as liraglutide and lixisenatide, have demonstrated effective central nervous system penetration, subsequently activating GLP-1 receptors and promoting neuroprotection and neuronal progenitor cell proliferation.120 Initial investigations into the neuroprotective effects of GLP-1RAs were conducted in diabetic animal models, where subcutaneous administration of liraglutide not only ameliorated hyperglycemia and peripheral insulin resistance, but also restored impaired brain insulin signaling, resulting in reduced tau hyperphosphorylation associated with AD pathology.121 Additionally, liraglutide enhanced learning and memory performance in diabetic mice.122 Notably, the beneficial effects of liraglutide on tau phosphorylation were not replicated by insulin therapy, suggesting that GLP-1RAs confer neuroprotection via mechanisms distinct from insulin signaling pathways.123 Following promising preclinical findings, several clinical trials have been initiated to evaluate the neuroprotective efficacy of GLP-1RAs in diverse populations, including individuals with diabetes, those at risk of cognitive decline, and patients diagnosed with AD or PD

The cost has come down significantly, said Dr

The Ultra-High Efficacy Seeker: Patients needing the absolute maximum weight reduction to meet surgical qualification criteria or to reverse severe comorbidities

Demand for such drugs is likely to continue to be strong in the future due to rising rates of obesity and interlinked chronic diseases